Related Experiment Video

Updated: Jul 13, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

MAGI3 inhibits renal clear cell carcinoma progression through the JAK-STAT3 pathway

Xiangqiu Chen1, Tao Wu1, Weifei Liang2

  • 1Department of Urology, Shenzhen Hospital, Southern Medical University, Shenzhen, China.

Translational Andrology and Urology
|July 12, 2026
PubMed
Abstract

Insights

MAGI3 is downregulated in clear cell renal cell carcinoma (ccRCC), acting as a tumor suppressor. Lower MAGI3 levels correlate with advanced ccRCC, indicating its potential as a prognostic biomarker.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Clear cell renal cell carcinoma (ccRCC) is the most prevalent kidney cancer subtype.
  • Limited therapeutic options for advanced ccRCC necessitate new prognostic markers and therapeutic targets.
  • The clinical significance and functional role of MAGI3 in ccRCC require clarification.

Purpose of the Study:

  • To investigate the clinical significance of MAGI3 in ccRCC.
  • To elucidate the functional role and underlying mechanisms of MAGI3 in ccRCC progression.
  • To evaluate MAGI3 as a potential prognostic biomarker for ccRCC.

Main Methods:

  • Analysis of MAGI3 expression in ccRCC and normal tissues using public datasets and clinical samples.
  • Correlation analysis of MAGI3 expression with clinicopathological features and patient survival.
  • In vitro and in vivo functional assays to determine the biological role of MAGI3 and its mechanism involving STAT3 signaling.

Main Results:

  • MAGI3 expression is significantly downregulated in ccRCC tissues compared to normal kidney specimens.
  • Lower MAGI3 levels correlate with advanced tumor stage, higher nuclear grade, lymph node metastasis, and increased immunosuppressive cells.
  • MAGI3 overexpression suppressed ccRCC cell proliferation, migration, and invasion by inhibiting STAT3 signaling.

Conclusions:

  • MAGI3 functions as a novel tumor suppressor in ccRCC, inhibiting cancer progression through the STAT3 pathway.
  • MAGI3 downregulation is associated with poor prognosis in ccRCC patients.
  • MAGI3 is a promising prognostic biomarker for ccRCC.
Keywords:
Clear cell renal cell carcinoma (ccRCC)JAK-STAT3MAGI3differentially expressed genes (DEGs)

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...